2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2595

S100A12 At Baseline May Be Useful for Predicting Inactive Disease within 12 Months in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 530

S100A8/A9 Is Upregulated and Triggers the Secretion of Pro-Inflammatory Cytokines in Primary Sjögren’s Syndrome
Abstract Number: 1678

Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
Abstract Number: 2031

Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin-1 Receptor Antagonist
Abstract Number: 1997

Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Abstract Number: 639

Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
Abstract Number: 1432

Safety and Efficacy of Etanercept in Systemic LUPUS Erythematosus
Abstract Number: 1677

Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children
Abstract Number: 502

Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Abstract Number: 1895

Safety Competences Knowledge and Behavioural Skills of Patients Treated by Biologics in Rheumatology
Abstract Number: 356

Safety of Abatacept in Rheumatoid Arthritis with Chronic Hepatitis B VIRUS Infection
Abstract Number: 180

Safety of Canakinumab in a Large Cohort of Patients with Cryopyrin-Associated Periodic Syndrome: Results From the ß-Confident Registry
Abstract Number: 1141

Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Abstract Number: 2054

Safety of Joint and Soft Tissue Injections in Patients On Warfarin Anti-Coagulation
Abstract Number: 2187

Safety of Minor Labial Salivary Gland Biopsy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].